<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p239" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_239{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_239{left:306px;bottom:30px;}
#t3_239{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_239{left:346px;bottom:30px;}
#t5_239{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_239{left:517px;bottom:30px;}
#t7_239{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_239{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_239{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_239{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_239{left:35px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#tc_239{left:35px;bottom:757px;letter-spacing:-0.38px;}
#td_239{left:59px;bottom:757px;letter-spacing:0.16px;}
#te_239{left:428px;bottom:757px;}
#tf_239{left:35px;bottom:722px;letter-spacing:0.12px;word-spacing:-0.34px;}
#tg_239{left:35px;bottom:702px;letter-spacing:0.04px;word-spacing:0.15px;}
#th_239{left:35px;bottom:683px;letter-spacing:0.02px;word-spacing:0.17px;}
#ti_239{left:35px;bottom:665px;letter-spacing:0.08px;word-spacing:0.1px;}
#tj_239{left:35px;bottom:645px;letter-spacing:0.16px;}
#tk_239{left:405px;bottom:645px;}
#tl_239{left:35px;bottom:608px;letter-spacing:0.08px;word-spacing:0.1px;}
#tm_239{left:35px;bottom:589px;letter-spacing:0.08px;word-spacing:-0.3px;}
#tn_239{left:35px;bottom:570px;letter-spacing:0.05px;word-spacing:0.14px;}
#to_239{left:35px;bottom:551px;letter-spacing:0.07px;word-spacing:0.11px;}
#tp_239{left:35px;bottom:531px;letter-spacing:0.16px;}
#tq_239{left:405px;bottom:531px;}
#tr_239{left:35px;bottom:495px;letter-spacing:0.11px;word-spacing:0.08px;}
#ts_239{left:35px;bottom:476px;letter-spacing:0.15px;word-spacing:0.04px;}
#tt_239{left:35px;bottom:457px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tu_239{left:35px;bottom:437px;letter-spacing:0.04px;word-spacing:-1.08px;}
#tv_239{left:35px;bottom:418px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tw_239{left:132px;bottom:418px;letter-spacing:0.16px;}
#tx_239{left:501px;bottom:418px;}
#ty_239{left:35px;bottom:382px;letter-spacing:0.03px;word-spacing:0.15px;}
#tz_239{left:35px;bottom:363px;letter-spacing:0.04px;word-spacing:0.15px;}
#t10_239{left:35px;bottom:343px;letter-spacing:0.01px;word-spacing:0.31px;}
#t11_239{left:35px;bottom:324px;letter-spacing:0.1px;word-spacing:0.09px;}
#t12_239{left:35px;bottom:304px;letter-spacing:0.16px;}
#t13_239{left:405px;bottom:304px;}
#t14_239{left:35px;bottom:269px;letter-spacing:0.03px;word-spacing:0.16px;}
#t15_239{left:35px;bottom:249px;letter-spacing:0.04px;word-spacing:-0.56px;}
#t16_239{left:35px;bottom:229px;word-spacing:0.19px;}
#t17_239{left:35px;bottom:210px;letter-spacing:0.04px;word-spacing:0.14px;}
#t18_239{left:35px;bottom:190px;letter-spacing:0.16px;}
#t19_239{left:396px;bottom:190px;}
#t1a_239{left:35px;bottom:155px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1b_239{left:35px;bottom:135px;letter-spacing:0.06px;word-spacing:-0.75px;}
#t1c_239{left:35px;bottom:116px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1d_239{left:35px;bottom:96px;letter-spacing:0.16px;}
#t1e_239{left:405px;bottom:96px;}
#t1f_239{left:618px;bottom:777px;word-spacing:0.19px;}
#t1g_239{left:618px;bottom:759px;letter-spacing:-0.01px;word-spacing:-0.86px;}
#t1h_239{left:618px;bottom:739px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1i_239{left:618px;bottom:720px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1j_239{left:618px;bottom:700px;letter-spacing:0.16px;}
#t1k_239{left:979px;bottom:700px;}
#t1l_239{left:618px;bottom:665px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1m_239{left:618px;bottom:645px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1n_239{left:618px;bottom:625px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1o_239{left:618px;bottom:606px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1p_239{left:618px;bottom:586px;letter-spacing:0.16px;}
#t1q_239{left:988px;bottom:586px;}
#t1r_239{left:618px;bottom:551px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1s_239{left:618px;bottom:531px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1t_239{left:618px;bottom:512px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1u_239{left:618px;bottom:492px;letter-spacing:0.16px;}
#t1v_239{left:988px;bottom:492px;}
#t1w_239{left:618px;bottom:457px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t1x_239{left:618px;bottom:437px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1y_239{left:618px;bottom:418px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1z_239{left:618px;bottom:398px;letter-spacing:0.07px;word-spacing:0.11px;}
#t20_239{left:618px;bottom:379px;letter-spacing:0.16px;}
#t21_239{left:988px;bottom:379px;}
#t22_239{left:618px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t23_239{left:618px;bottom:324px;letter-spacing:0.08px;word-spacing:0.1px;}
#t24_239{left:618px;bottom:304px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t25_239{left:618px;bottom:284px;letter-spacing:0.04px;word-spacing:0.15px;}
#t26_239{left:618px;bottom:265px;letter-spacing:0.16px;}
#t27_239{left:988px;bottom:265px;}
#t28_239{left:618px;bottom:229px;letter-spacing:0.06px;word-spacing:0.12px;}
#t29_239{left:618px;bottom:210px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2a_239{left:618px;bottom:190px;letter-spacing:0.02px;word-spacing:0.32px;}
#t2b_239{left:618px;bottom:172px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2c_239{left:618px;bottom:152px;letter-spacing:0.16px;}
#t2d_239{left:988px;bottom:152px;}
#t2e_239{left:618px;bottom:116px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2f_239{left:618px;bottom:96px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2g_239{left:618px;bottom:78px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t2h_239{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_239{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_239{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_239{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_239{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_239{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_239{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_239{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts239" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg239Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg239" style="-webkit-user-select: none;"><object width="1210" height="935" data="239/239.svg" type="image/svg+xml" id="pdf239" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_239" class="t s0_239">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_239" class="t s1_239">© </span>
<span id="t3_239" class="t s0_239">(NCCN </span>
<span id="t4_239" class="t s1_239">© </span>
<span id="t5_239" class="t s0_239">), All rights reserved. NCCN Guidelines </span>
<span id="t6_239" class="t s1_239">® </span>
<span id="t7_239" class="t s0_239">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_239" class="t s2_239">NCCN Guidelines Version 4.2024 </span>
<span id="t9_239" class="t s2_239">Head and Neck Cancers </span>
<span id="ta_239" class="t s3_239">MS-98 </span>
<span id="tb_239" class="t s4_239">phase 3 randomized clinical trial. JAMA Oncol 2022;8:553-561. Available </span>
<span id="tc_239" class="t s4_239">at: </span><span id="td_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/35175316</span><span id="te_239" class="t s4_239">. </span>
<span id="tf_239" class="t s4_239">523. Tang LL, Chen YP, Mao YP, et al. Validation of the 8th edition of the </span>
<span id="tg_239" class="t s4_239">UICC/AJCC staging system for nasopharyngeal carcinoma from endemic </span>
<span id="th_239" class="t s4_239">areas in the intensity-modulated radiotherapy era. J Natl Compr Canc </span>
<span id="ti_239" class="t s4_239">Netw 2017;15:913-919. Available at: </span>
<span id="tj_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/28687579</span><span id="tk_239" class="t s4_239">. </span>
<span id="tl_239" class="t s4_239">524. Guo R, Tang LL, Mao YP, et al. Proposed modifications and </span>
<span id="tm_239" class="t s4_239">incorporation of plasma Epstein-Barr virus DNA improve the TNM staging </span>
<span id="tn_239" class="t s4_239">system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer </span>
<span id="to_239" class="t s4_239">2019;125:79-89. Available at: </span>
<span id="tp_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/30351466</span><span id="tq_239" class="t s4_239">. </span>
<span id="tr_239" class="t s4_239">525. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus </span>
<span id="ts_239" class="t s4_239">concurrent chemoradiotherapy versus concurrent chemoradiotherapy </span>
<span id="tt_239" class="t s4_239">alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, </span>
<span id="tu_239" class="t s4_239">multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509-1520. </span>
<span id="tv_239" class="t s4_239">Available at: </span><span id="tw_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/27686945</span><span id="tx_239" class="t s4_239">. </span>
<span id="ty_239" class="t s4_239">526. Zhang Y, Chen L, Hu GQ, et al. Final overall survival analysis of </span>
<span id="tz_239" class="t s4_239">gemcitabine and cisplatin induction chemotherapy in nasopharyngeal </span>
<span id="t10_239" class="t s4_239">carcinoma: a multicenter, randomized phase III trial. J Clin Oncol </span>
<span id="t11_239" class="t s4_239">2022;40:2420-2425. Available at: </span>
<span id="t12_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/35709465</span><span id="t13_239" class="t s4_239">. </span>
<span id="t14_239" class="t s4_239">527. Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong </span>
<span id="t15_239" class="t s4_239">P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin </span>
<span id="t16_239" class="t s4_239">and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head </span>
<span id="t17_239" class="t s4_239">Neck Oncol 2011;3:30. Available at: </span>
<span id="t18_239" class="t s5_239">http://www.ncbi.nlm.nih.gov/pubmed/21639934</span><span id="t19_239" class="t s4_239">. </span>
<span id="t1a_239" class="t s4_239">528. Songthong A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C. </span>
<span id="t1b_239" class="t s4_239">Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in </span>
<span id="t1c_239" class="t s4_239">nasopharyngeal carcinoma. Radiol Oncol 2015;49:155-162. Available at: </span>
<span id="t1d_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/26029027</span><span id="t1e_239" class="t s4_239">. </span>
<span id="t1f_239" class="t s4_239">529. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. </span>
<span id="t1g_239" class="t s4_239">Chemoradiation comparing cisplatin versus carboplatin in locally advanced </span>
<span id="t1h_239" class="t s4_239">nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J </span>
<span id="t1i_239" class="t s4_239">Cancer 2007;43:1399-1406. Available at: </span>
<span id="t1j_239" class="t s5_239">http://www.ncbi.nlm.nih.gov/pubmed/17467265</span><span id="t1k_239" class="t s4_239">. </span>
<span id="t1l_239" class="t s4_239">530. Rusthoven CG, Lanning RM, Jones BL, et al. Metastatic </span>
<span id="t1m_239" class="t s4_239">nasopharyngeal carcinoma: Patterns of care and survival for patients </span>
<span id="t1n_239" class="t s4_239">receiving chemotherapy with and without local radiotherapy. Radiother </span>
<span id="t1o_239" class="t s4_239">Oncol 2017;124:139-146. Available at: </span>
<span id="t1p_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/28433411</span><span id="t1q_239" class="t s4_239">. </span>
<span id="t1r_239" class="t s4_239">531. Chua GWY, Chua ET. Long-term disease-free survival of a patient </span>
<span id="t1s_239" class="t s4_239">with oligometastatic nasopharyngeal carcinoma treated with radiotherapy </span>
<span id="t1t_239" class="t s4_239">alone. Case Rep Oncol 2018;11:392-398. Available at: </span>
<span id="t1u_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/30022942</span><span id="t1v_239" class="t s4_239">. </span>
<span id="t1w_239" class="t s4_239">532. Ma J, Wen ZS, Lin P, et al. The results and prognosis of different </span>
<span id="t1x_239" class="t s4_239">treatment modalities for solitary metastatic lung tumor from </span>
<span id="t1y_239" class="t s4_239">nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J </span>
<span id="t1z_239" class="t s4_239">Cancer 2010;29:787-795. Available at: </span>
<span id="t20_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/20800020</span><span id="t21_239" class="t s4_239">. </span>
<span id="t22_239" class="t s4_239">533. You R, Liu YP, Huang PY, et al. Efficacy and safety of locoregional </span>
<span id="t23_239" class="t s4_239">radiotherapy with chemotherapy vs chemotherapy alone in de novo </span>
<span id="t24_239" class="t s4_239">metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized </span>
<span id="t25_239" class="t s4_239">clinical trial. JAMA Oncol 2020;6:1345-1352. Available at: </span>
<span id="t26_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/32701129</span><span id="t27_239" class="t s4_239">. </span>
<span id="t28_239" class="t s4_239">534. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus </span>
<span id="t29_239" class="t s4_239">fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal </span>
<span id="t2a_239" class="t s4_239">carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet </span>
<span id="t2b_239" class="t s4_239">2016;388:1883-1892. Available at: </span>
<span id="t2c_239" class="t s5_239">https://www.ncbi.nlm.nih.gov/pubmed/27567279</span><span id="t2d_239" class="t s4_239">. </span>
<span id="t2e_239" class="t s4_239">535. Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus </span>
<span id="t2f_239" class="t s4_239">fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic </span>
<span id="t2g_239" class="t s4_239">nasopharyngeal carcinoma: final overall survival analysis of </span>
<span id="t2h_239" class="t s6_239">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
